{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T06:04:52Z","timestamp":1774073092614,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jfo.2024.104387","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T11:17:56Z","timestamp":1734520676000},"page":"104387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["\u00c9tude de vraie vie sur 6\u00a0mois d\u2019un protocole de traitement intravitr\u00e9en de la toxoplasmose oculaire par clindamycine"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9906-4061","authenticated-orcid":false,"given":"F.P.","family":"Roubelat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0107-447X","authenticated-orcid":false,"given":"F.","family":"Varenne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3941-1304","authenticated-orcid":false,"given":"V.","family":"Gualino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Pugnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Civade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1407-106X","authenticated-orcid":false,"given":"N.","family":"Bataille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Bruzard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Barioulet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Adam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9224-2351","authenticated-orcid":false,"given":"P.","family":"Fourni\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Soler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2024.104387_bib0125","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.ajo.2003.09.040","article-title":"Ocular toxoplasmosis: a global reassessment","volume":"136","author":"Holland","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104387_bib0130","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s40268-017-0206-8","article-title":"Adverse event profile of pyrimethamine-based therapy in toxoplasmosis: a systematic review","volume":"17","author":"Ben-Harari","year":"2017","journal-title":"Drugs R D"},{"key":"10.1016\/j.jfo.2024.104387_bib0135","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41598-020-80569-7","article-title":"Adverse outcomes associated with the treatment of Toxoplasma infections","volume":"11","author":"Shammaa","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfo.2024.104387_bib0140","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1023\/A:1006129422690","article-title":"Successful management of ocular toxoplasmosis during pregnancy using combined intraocular clindamycin and dexamethasone with systemic sulfadiazine","volume":"22","author":"Martinez","year":"1998","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104387_bib0145","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3928\/1542-8877-20010501-03","article-title":"Intravitreal clindamycin and dexamethasone for toxoplasmic retinochoroiditis","volume":"32","author":"Kishore","year":"2001","journal-title":"Ophthalmic Surg Lasers"},{"key":"10.1016\/j.jfo.2024.104387_bib0150","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1097\/IAE.0b013e31804b3f0d","article-title":"Intravitreal clindamycin for toxoplasmic retinochoroiditis","volume":"27","author":"Sobrin","year":"2007","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2024.104387_bib0155","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ophtha.2010.04.020","article-title":"Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis","volume":"118","author":"Soheilian","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104387_bib0160","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10792-012-9634-1","article-title":"Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial","volume":"33","author":"Baharivand","year":"2013","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104387_bib0165","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0002-9394(14)78240-6","article-title":"Signs and symptoms of uveitis*","volume":"47","author":"Kimura","year":"1959","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104387_bib0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/4160837","article-title":"Intravitreal clindamycin and dexamethasone combined with systemic oral antitoxoplasma therapy versus intravitreal therapy alone in the management of toxoplasma retinochoroiditis: a retrospective study","volume":"2018","author":"Bor\u2019i","year":"2018","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104387_bib0175","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.ophtha.2010.01.028","article-title":"Intravitreal clindamycin and dexamethasone for zone 1 toxoplasmic retinochoroiditis at twenty-four months","volume":"117","author":"Lasave","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104387_bib0180","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.2147\/OPTH.S288725","article-title":"Intravitreal clindamycin as first-line therapy for toxoplasmic retinochoroiditis: a case series","volume":"14","author":"Verma","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104387_bib0185","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jfo.2021.04.001","article-title":"Injection intravitr\u00e9enne de clindamycine dans le traitement des r\u00e9tinochoro\u00efdites toxoplasmiques\u00a0: \u00e0 propos de 9 cas dans le service d\u2019ophtalmologie du CHU de Bordeaux","volume":"44","author":"Handaye-Dessus","year":"2021","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2024.104387_bib0190","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jpba.2014.08.023","article-title":"Development of a method to quantify clindamycin in vitreous humor of rabbits\u2019 eyes by UPLC\u2013MS\/MS: application to a comparative pharmacokinetic study and in vivo ocular biocompatibility evaluation","volume":"102","author":"Fernandes-Cunha","year":"2015","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.jfo.2024.104387_bib0195","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jfo.2012.02.009","article-title":"Efficacit\u00e9 d\u2019un traitement prophylactique hypotonisant dans l\u2019hypertonie oculaire induite apr\u00e8s injections intravitr\u00e9ennes","volume":"35","author":"El Chehab","year":"2012","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2024.104387_bib0200","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.ajo.2013.12.022","article-title":"Trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrences of toxoplasma gondii retinochoroiditis: randomized controlled clinical trial","volume":"157","author":"Felix","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104387_bib0205","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3109\/09273948.2014.964422","article-title":"The effect of long-term intermittent trimethoprim\/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis: 10 years of follow-up","volume":"23","author":"Silveira","year":"2015","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jfo.2024.104387_bib0210","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/bjophthalmol-2022-321091","article-title":"Current practice in the management of ocular toxoplasmosis","volume":"107","author":"Yogeswaran","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104387_bib0215","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jfo.2021.11.007","article-title":"Prise en charge de la toxoplasmose oculaire en France\u00a0: r\u00e9sultats d\u2019une \u00e9tude Delphi modifi\u00e9e","volume":"45","author":"Schaeffer","year":"2022","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2024.104387_bib0220","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/09273948.2016.1215471","article-title":"Current practices in ocular toxoplasmosis: a survey of Brazilian uveitis specialists","volume":"26","author":"Morais","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jfo.2024.104387_bib0225","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1442-6404.2002.00502.x","article-title":"Hypersensitivity reaction to intravitreal clindamycin therapy: hypersensitivity to intravitreal clindamycin","volume":"30","author":"Kim","year":"2002","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104387_bib0230","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4103\/joco.joco_150_20","article-title":"Macular infarction following intravitreal clindamycin injection: a case report","volume":"33","author":"Hedayatfar","year":"2021","journal-title":"J Curr Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104387_bib0235","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10633-017-9599-5","article-title":"Safety of intravitreal clindamycin in albino rabbit eyes","volume":"135","author":"Habot-Wilner","year":"2017","journal-title":"Doc Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104387_bib0120","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3928\/23258160-20150101-27","article-title":"The role of intravitreal trimethoprim\/sulfamethoxazole in the treatment of toxoplasma retinochoroiditis","volume":"46","author":"Choudhury","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retina"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551224003322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551224003322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T16:46:42Z","timestamp":1737650802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551224003322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0181551224003322"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2024.104387","relation":{},"ISSN":["0181-5512"],"issn-type":[{"value":"0181-5512","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00c9tude de vraie vie sur 6\u00a0mois d\u2019un protocole de traitement intravitr\u00e9en de la toxoplasmose oculaire par clindamycine","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2024.104387","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104387"}}